卡利拉嗪辅助治疗重性抑郁障碍的随机双盲安慰剂对照3期研究
这项随机双盲安慰剂对照3期研究纳入对至少一种抗抑郁药单药治疗应答不足的重性抑郁障碍成人患者,按1:1:1随机分配至安慰剂、卡利拉嗪1.5 mg/日或3.0 mg/日组。主要终点为第6周MADRS总分自基线变化。结果显示卡利拉嗪1.5 mg/日组MADRS减分显著优于安慰剂(-14.1 vs. -11.5),3.0 mg/日组未达显著;1.5 mg/日组应答率显著更高(44.0% vs. 34.9%),缓解率组间无显著差异。常见不良事件为静坐不能和恶心。
要点
- 卡利拉嗪1.5 mg/日辅助治疗第6周MADRS减分显著优于安慰剂。
- 卡利拉嗪3.0 mg/日组MADRS减分未显著优于安慰剂。
- 1.5 mg/日组应答率显著高于安慰剂,缓解率组间无显著差异。
核心结论
- 卡利拉嗪1.5 mg/日辅助治疗对单药抗抑郁药应答不足的重性抑郁障碍成人患者有效,且总体耐受性良好。
研究设计与样本
- 随机、双盲、安慰剂对照3期研究,纳入对至少一种抗抑郁药单药治疗应答不足的重性抑郁障碍成人患者。
- 按1:1:1随机分配至安慰剂、卡利拉嗪1.5 mg/日或卡利拉嗪3.0 mg/日组。
- 改良意向治疗(mITT)人群共751例(安慰剂N=249;卡利拉嗪1.5 mg/日N=250;卡利拉嗪3.0 mg/日N=252)。
主要发现
- 第6周MADRS总分自基线平均减分:卡利拉嗪1.5 mg/日组-14.1,安慰剂组-11.5,差异显著。
- 第6周MADRS总分自基线平均减分:卡利拉嗪3.0 mg/日组-13.1,与安慰剂差异不显著。
- 卡利拉嗪1.5 mg/日组与安慰剂组在第2周和第4周也观察到显著差异。
- 达到MADRS应答标准的比例:卡利拉嗪1.5 mg/日组44.0%,安慰剂组34.9%,差异显著。
- 缓解率在各组间无显著差异。
关键数值与推荐
- 主要终点为第6周MADRS总分自基线变化,采用混合效应模型重复测量并校正多重比较。
- 常见治疗中出现的不良事件(任一卡利拉嗪组≥5%且为安慰剂组两倍)为静坐不能和恶心。
临床怎么用
- 对于对至少一种抗抑郁药单药治疗应答不足的重性抑郁障碍成人患者,可考虑联用卡利拉嗪1.5 mg/日辅助治疗。
- 使用卡利拉嗪时需关注静坐不能和恶心等不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The purpose of this study was to investigate the efficacy of cariprazine, a dopamine D3-preferring D3/D2 and serotonin 5-HT1A receptor partial agonist, as adjunctive therapy for patients with major depressive disorder and nonresponse to at least one antidepressant monotherapy. METHODS: In this double-blind placebo-controlled study, adults with major depressive disorder and inadequate response to antidepressants alone were randomized in a 1:1:1 ratio to placebo, cariprazine at 1.5 mg/day, or cariprazine at 3.0 mg/day. The primary outcome was change from baseline to week 6 in total score on the Montgomery-Åsberg Depression Rating Scale (MADRS). Least-squares mean differences were estimated in the modified intent-to-treat (mITT) population using a mixed-effects model for repeated measures with adjustment for multiple comparisons. RESULTS: The mITT population comprised 751 patients (placebo: N=249; cariprazine 1.5 mg/day: N=250; cariprazine 3.0 mg/day: N=252). At week 6, the mean reduction from baseline in MADRS total score was significantly greater with cariprazine 1.5 mg/day than with placebo (-14.1 vs. -11.5) but not with cariprazine 3.0 mg/day (-13.1). Significant differences between the cariprazine 1.5 mg/day and placebo groups were also observed at weeks 2 and 4. Meeting the MADRS response criteria was significantly more likely among patients receiving cariprazine 1.5 mg/day than placebo (44.0% vs. 34.9%); remission rates were not significantly different among groups. Common treatment-emergent adverse events (≥5% in either cariprazine group and twice the placebo rate) were akathisia and nausea. CONCLUSIONS: Adjunctive cariprazine at 1.5 mg/day demonstrated efficacy in reducing depressive symptoms in adults with major depressive disorder and inadequate response to antidepressants alone. Cariprazine was generally well tolerated, with a safety profile that was consistent with previous findings.
引用
- Sachs GS, Yeung PP, Rekeda L, et al. Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. Am J Psychiatry. 2023. PMID: 36789515. doi:10.1176/appi.ajp.20220504
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。